Latest Share Chat

VEC.L Share News (VEC)

VEC.L Information

There is currently no data for VEC

Skyepharma and Vectura agree merger; Skyepharma swings to profit

Wed, 16th Mar 2016 08:55

(ShareCast News) - Vectura and Skyepharma have reached an agreement on the terms of a recommended merger.Under the terms of the deal, Skyepharma shareholders will get 2.7977 new Vectura shares for each Skyepharma share. Based on Vectura's closing price of 146.60p on Tuesday, this values Skyepharma at 410.15p per share or around £441.13m.There will also be a partial cash alternative of up to £70m pursuant to which Skyepharma shareholders can elect to receive cash instead of some or all of the new Vectura shares to which they would otherwise be entitled under the merger.The combined group's executive directors will comprise James Ward-Lilley, Vectura's chief executive officer, Andrew Derodra, Skyepharma's chief financial officer and Trevor Phillips, Vectura's chief operating officer.Vectura chairman Bruno Angelici will be chairman of the enlarged group.Also on Wednesday, Skyepharma said it swung to a pre-tax profit of £30.5m in the year to the end of December, compared with a loss of £9.9m in 2014, as revenue rose 30% to £95.6m.The company, which specialises in oral and inhalation drug development, said it reached its first sales milestone for Flutiform of €10m (£7.4m) in the year.Chief executive officer Peter Grant said: "2015 has been a year of further substantial progress both operationally and financially. Our proven expertise in developing innovative inhalation and oral products has given us a track record of growth that reinforces our optimism about the future."With a sustained focus on expertise, innovation and growth, we have entered 2016 with a high degree of confidence in our business."Dr Samir Devani, managing director of Rx Securities, said the deal was likely to be significantly earnings-enhancing for Vectura shareholders and will provide stronger long-term growth for Skyepharma shareholders. Devani said that strategically, the deal has strong rationale, with complimentary respiratory technologies, and would provide "a true one-stop shop for respiratory development", a strong combined pipeline, a more diversified revenue composition and a stronger balance sheet. "Significant M&A has been long-overdue in the biotech space and we view this deal as particularly positive due to the strong technology complementarity and the building of a major respiratory powerhouse," he said, as he reiterated his 'buy' rating on Skyepharma.At 1342 GMT, Vectura shares were up 2.3% to 149.90p and Skyepharma was up 3.9% to 409p.

More News

19 Apr 2018 12:53

hVIVO CEO Steps Down In Favour Of Executive Chair As Loss Narrows

LONDON (Alliance News) - Clinical development and drug discovery business hVIVO PLC said Thursday its loss narrowed in 2017 as Chief Executive Kym Denny stepped aside for Executive Chairman Trevor

3 Apr 2018 08:41

EUROPE RESEARCH ROUNDUP-Aevis Victoria, Martela Oyj, Mediaset

April 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Aevis Victoria, Martela Oyj and Mediaset, on Tuesday. HIGHLIGHTS * Aevis SA

23 Mar 2018 18:23

DIRECTOR DEALINGS: Vectura Non-Executive Juliet Thompson Buys Shares

LONDON (Alliance News) - Vectura Group PLC said Friday Non-Executive Director Juliet Thompson bought shares worth GBP36,284 in the pharmaceutical company after

22 Mar 2018 16:16

DIRECTOR DEALINGS: Vectura Chairman, Non-Exec Director Buy Shares

LONDON (Alliance News) - Vectura Group PLC said on Thursday that two directors bought shares in the company on Wednesday.Chairman Bruno Angelici purchased 75,000 shares

21 Mar 2018 08:52

Vectura Delivers "Good" 2017 Results Despite Advair Disappointment

LONDON (Alliance News) - Pharmaceutical firm Vectura Group PLC said Wednesday it delivered a "good" set of 2017 results with underlying profit and revenue growth to

21 Mar 2018 08:31

UPDATE 1-UK's Vectura posts wider 2017 loss, revenue rise

March 21 (Reuters) - British drugmaker Vectura reported a worse-than-expected pretax loss for the full year on Wednesday, dragged by lower royalties and higher costs related to the SkyePharma for

21 Mar 2018 07:47

UPDATE 1-UK Stocks-Factors to watch on March 21

March 21 (Reuters) - Britain's FTSE 100 index is seen opening up 13 points on Wednesday, according to financial bookmakers, with futures 0.26 pct higher ahead of the cash

21 Mar 2018 07:40

Drugmaker Vectura's 2017 revenue rises 17.2 pct

March 21 (Reuters) - British drugmaker Vectura reported a 17.2 percent rise in 2017 revenue on Wednesday, aided by higher demand for its asthma products Flutiform and Ultibro. The company,

20 Mar 2018 13:21

Legal & General Increases Vectura Stake To 3.7% From Below 3% (ALLISS)

LONDON (Alliance News) - Vectura Group PLC said Tuesday FTSE 100-listed insurer and asset manager Legal & General Group PLC increased its stake in the pharmaceutical firm

14 Mar 2018 16:20

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 15 March Old MutualFull Year ResultsPhoenix GroupFull Year GroupFull 16

12 Mar 2018 10:43

WINNERS & LOSERS SUMMARY: Vectura And Hikma Hurt By US FDA Ruling

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------easyJet, up 2.3% at on

12 Mar 2018 09:43

FTSE 100 lags Europe on miners and energy, Just Eat goes cold

(For a live blog on European stocks, type LIVE/ in an Eikon news window) * FTSE 100 up 0.1 pct * Just Eat hit by DB downgrade * Vectura, Hikma hit by delay to Advair GKN up 12

16 Feb 2017 07:49

Vectura Hits GBP9 Million Royalty Cap Under Skyepharma Legacy Deal

16 Feb 2017 07:06

Vectura's GSK royalties agreements firing on all cylinders

(ShareCast News) - Vectura Group hit its royalty cap on sales of GlaxoSmithKline´s Ellipta range of products in 2016, one year ahead of forecasts. The cap was equivalent to £9.0m. The inhaled airways disease-focused business was also set to record £5.4m of 2016 revenues under a separate single digi

8 Feb 2017 13:49

UPDATE 1-Weak pound buoys GSK but drugmaker warns on 2017 generic threat

* 2017 core EPS seen flat-lower if mid-year generic Advair * Current exchange rates would lift 2017 sterling EPS 9 pct * Q4 2016 core EPS 26.1 pence vs consensus forecast 25.0p (Adds CEO comments, shares, background on new CEO) By Ben Hirschler LONDON, Feb 8 (Reuters) -

Latest Share Chat

VEC.L Share News (VEC)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Skyepharma and Vectura agree merger; Skyepharma swings to profit

Login to your account

Quickpicks are a member only feature

Login to your account